JP2003500360A - ボロプロリン化合物類を含む抗癌剤 - Google Patents

ボロプロリン化合物類を含む抗癌剤

Info

Publication number
JP2003500360A
JP2003500360A JP2000619438A JP2000619438A JP2003500360A JP 2003500360 A JP2003500360 A JP 2003500360A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2000619438 A JP2000619438 A JP 2000619438A JP 2003500360 A JP2003500360 A JP 2003500360A
Authority
JP
Japan
Prior art keywords
cancer
drug
subject
agent
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000619438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500360A5 (enExample
Inventor
ピー． ウォールナー，バーバラ
ミラー，グレン
Original Assignee
ポイント セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポイント セラピューティクス， インコーポレイテッド filed Critical ポイント セラピューティクス， インコーポレイテッド
Publication of JP2003500360A publication Critical patent/JP2003500360A/ja
Publication of JP2003500360A5 publication Critical patent/JP2003500360A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000619438A 1999-05-25 2000-05-25 ボロプロリン化合物類を含む抗癌剤 Pending JP2003500360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13586199P 1999-05-25 1999-05-25
US60/135,861 1999-05-25
PCT/US2000/014505 WO2000071135A1 (en) 1999-05-25 2000-05-25 Anti-tumor comprising boroproline compounds

Publications (2)

Publication Number Publication Date
JP2003500360A true JP2003500360A (ja) 2003-01-07
JP2003500360A5 JP2003500360A5 (enExample) 2007-07-19

Family

ID=22470056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000619438A Pending JP2003500360A (ja) 1999-05-25 2000-05-25 ボロプロリン化合物類を含む抗癌剤

Country Status (6)

Country Link
EP (1) EP1187619A1 (enExample)
JP (1) JP2003500360A (enExample)
AU (1) AU781897B2 (enExample)
CA (1) CA2373643A1 (enExample)
HK (1) HK1046846A1 (enExample)
WO (1) WO2000071135A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533727A (ja) * 2011-11-22 2014-12-15 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2018056907A1 (en) * 2016-09-21 2018-03-29 Agency For Science, Technology And Research Methods and compositions for inhibiting skin inflammation and determining cancer susceptibility
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
TWI812820B (zh) * 2018-12-10 2023-08-21 美商百歐克斯賽爾治療公司 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
CN115779148B (zh) * 2021-09-09 2024-02-23 中国科学院福建物质结构研究所 一种牙种植体表面涂层及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
WO1998050046A1 (en) * 1997-05-07 1998-11-12 Trustees Of Tufts College Use of cd26 inhibitor for the manufacture of a medicament for the treatment of hiv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328936A (en) * 1993-02-01 1994-07-12 Rohm And Haas Company Polymerization process for making porous polymeric particles
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
AU765370B2 (en) * 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
WO1998050046A1 (en) * 1997-05-07 1998-11-12 Trustees Of Tufts College Use of cd26 inhibitor for the manufacture of a medicament for the treatment of hiv

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533727A (ja) * 2011-11-22 2014-12-15 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー
JP2017214420A (ja) * 2011-11-22 2017-12-07 トラスティーズ オブ タフツ カレッジ 樹状細胞癌ワクチンのための小分子エンハンサー

Also Published As

Publication number Publication date
AU5292700A (en) 2000-12-12
AU781897B2 (en) 2005-06-23
CA2373643A1 (en) 2000-11-30
EP1187619A1 (en) 2002-03-20
WO2000071135A1 (en) 2000-11-30
HK1046846A1 (zh) 2003-01-30

Similar Documents

Publication Publication Date Title
US7259138B2 (en) Anti-tumor agents
AU781897B2 (en) Anti-tumor comprising boroproline compounds
JP5075927B2 (ja) 固形腫瘍を予防および治療するための方法および組成物
US11433136B2 (en) Polyacetal polymers, conjugates, particles and uses thereof
Su et al. Role of CXCR4 in the progression and therapy of acute leukaemia
KR101483802B1 (ko) 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도
CN112867503A (zh) 掩蔽的细胞因子缀合物
WO2021012886A1 (zh) 一种抗肿瘤的联合用药物组合物及其应用
CN101068561A (zh) 用于加强抗血管生成疗法的方法和组合物
US20050267027A1 (en) Use of erythropoietin for treatment of cancer
Rajkumar Thalidomide in the treatment of multiple myeloma
US20240288425A1 (en) Selection of patients for combination therapy
US8232318B2 (en) Approaches to treat cancer using HB-EGF inhibitors
Zhang et al. Anti-angiogenic therapies in cancer clinical trials
JP7535285B2 (ja) 腫瘍関連マクロファージ賦活化剤
WO2023039399A2 (en) Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP1806138A1 (en) Anti-tumor agents comprising boroproline compounds
AU2005211682A1 (en) Anti-tumor comprising boroproline compounds
US20240216465A1 (en) Method for treating refractory brain tumor
Teicher 17 Potentiation of Cytotoxic Cancer
Korpela Improving Cancer Radiotherapy Outcomes with Vasculotide, an Angiopoietin-1 Mimetic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308